Therapeutic Uses
Antibiotics
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
(2R,3S,4S,5S,6R)-6-(((3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-(((2R,3S,4R,5S)-3,4-Dihydroxy-6,6-dimethyl-5-((2-(methyl-d3)propanoyl-2,3,3,3-d4)oxy)tetrahydro-2H-pyran-2-yl)oxy)-11-ethyl-8-hydroxy-18-((R)-1-hydroxyethyl)-9,13,15-trimethyl-2-oxooxacyclooctadeca-3,5,9,13,15-pentaen-3-yl)methoxy)-4-hydroxy-5-methoxy-2-methyltetrahydro-2H-pyran-3-yl-3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Fidaxomicin-d7 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Fidaxomicin-d7 usage and description
Fidaxomicin D7 is a derivative of the antibiotic Fidaxomicin, which is used for the treatment of Clostridium difficile-associated diarrhea (CDAD). It is a macrocyclic antibiotic that selectively targets the RNA polymerase of C. difficile, which is responsible for the replication of the bacterium. Fidaxomicin D7 is a deuterated form of Fidaxomicin, which means that seven of its hydrogen atoms have been replaced by deuterium atoms. This modification enhances the drug's stability and prolongs its half-life, allowing for less frequent dosing.
The chemical structure of Fidaxomicin D7 consists of a macrocycle with a unique spiroketal moiety, which is responsible for its potent antibacterial activity. The drug is administered orally and is rapidly absorbed in the intestine. It is metabolized in the liver and excreted primarily in the feces, with a small portion being eliminated in the urine.
Fidaxomicin D7 is highly effective in the treatment of CDAD, with a cure rate of up to 90%. It has also been shown to have a lower rate of recurrence compared to other antibiotics used for CDAD. However, it is important to note that Fidaxomicin D7 is a prescription-only drug and should only be used under the guidance of a healthcare professional. Additionally, it is important to follow the prescribed dosing regimen and complete the full course of treatment to ensure maximum effectiveness and minimize the development of antibiotic resistance.
